SAN DIEGO, Calif. — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.
“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas,” said Mark Lappe, Chief Executive Officer of Inhibrx. “In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options. Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible.”
Ewing Sarcoma
As of the September 18, 2026, data cutoff, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumor size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.
The median progression free survival (mPFS) was 6.0 months (95% CI: 4.6–7.4). Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.
These data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and a mPFS of roughly 3 to 4 months.
The combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.
The FDA accepted for filing our biologics license application for the potential approval of ozekibart in conventional chondrosarcoma. With approximately 300 new cases of Ewing sarcoma diagnosed each year in the U.S. and an estimated 2,500 individuals in the U.S. currently living with Ewing sarcoma, the need for novel therapeutic options in this underserved community is profound, and we look forward to discussing these results with the FDA.
Presentation Materials
Ewing Sarcoma Poster Details:
- Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
- Session: Poster Presentation Session
- Abstract Number: 2465416
- Presenter: Varun Monga, M.D.
- Date: Thursday, November 19, 2026
The poster materials will be made available in the “Events & Presentations” section of the Inhibrx Biosciences investor portal at inhibrxbiosciences.
About ozekibart (INBRX-109)
Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. Ozekibart is engineered to optimize tumor-biased receptor clustering and activation without requiring secondary crosslinking, avoiding the severe hepatotoxicity observed with first-generation DR5-targeting agents.
About Inhibrx Biosciences, Inc.
Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx’s current clinical pipeline of therapeutic candidates includes ozekibart and ordastobart (INBRX-106), both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what Inhibrx believes to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.
Investor and Media Contact
Kelly Deck, CFO
858-795-4260
